Clinical Trial Update: Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a combination of GNS561 and trametinib in advanced KRAS-mutated cholangiocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• GNS561
• Trametinib (trametinib)

Snippet

Sponsor: Genfit | Conditions: Cholangiocarcinoma | Phase 1, Phase 2 | Status: RECRUITING